A 75-year-old Saudi male farmer with a history of type 2 diabetes mellitus presented with a 3-month progressive neurological decline. Initial symptoms included impaired hand coordination and task sequencing, followed by visual and auditory hallucinations. A short febrile illness with vomiting ensued, after which he developed cachexia, postural instability, frequent falls, bradykinesia, bilateral tremors, hypophonia, incontinence, and cognitive deterioration.

He denied recent travel or consumption of unpasteurized dairy products but had over 20 years of close contact with cattle, goats, and sheep.

Neurologic examination revealed inattention, non-fluent aphasia, impaired recall (MoCA 9/26), bilateral resting and kinetic tremors, lower limb rigidity, bradykinesia, and reduced strength (Medical Research Council (MRC) 3/5 right side, 2/5 left side). Hyperreflexia was present. Full sensory and cerebellar assessment was limited by his attentional deficits.

Routine labs were unremarkable except for an elevated HbA1c. Brucella serology was strongly positive (>1:1280), and thyroid peroxidase antibodies were also elevated. Although Brucella species could not be isolated by culture, the diagnosis was supported by serology and confirmed by a positive CSF Brucella PCR. An initial cerebrospinal fluid (CSF) analysis showed elevated protein (2.97 g/L) and mild pleocytosis (12 WBCs/mm³, 75% lymphocytes). A second lumbar puncture, performed approximately 2 weeks later, revealed turbid CSF, increased WBCs (14/mm³, 70% neutrophils), higher protein (3.37 g/L), and a slightly low glucose (4.6 mmol/L).

An initial brain MRI showed right temporal cortical lesions, acute frontoparietal lacunar infarcts, background microangiopathy, and atrophy. A second MRI, obtained 2 weeks later, demonstrated diffuse pachymeningeal and leptomeningeal enhancement (Figure 1). A third MRI, done about 2 months later, showed persistent pachymeningeal enhancement and a new focal lesion in the left temporal convexity, without acute ischemia.

He was started on a combination antibiotic regimen consisting of oral doxycycline (100 mg twice daily), oral rifampin (600 mg once daily), oral sulfamethoxazole-trimethoprim (800/160 mg twice daily), and intravenous ceftriaxone (2 g once daily, administered intermittently). This initial course continued for approximately 2.5 months. Due to persistently elevated CSF protein levels despite clinical and radiologic improvement, a second antibiotic course of the same oral regimen (doxycycline, rifampin, and sulfamethoxazole-trimethoprim) was administered for an additional 6 weeks. Corticosteroids (oral dexamethasone 4 mg every 6 h) were given concurrently during the first month and then tapered over 3 weeks in response to persistent imaging abnormalities.

CSF Brucella PCR became negative, and serological titers declined to 1:640, indicating microbiological response.

The patient’s clinical condition improved substantially, with resolution of hallucinations, bradykinesia, and rigidity. Strength improved to 4/5 in all limbs, though mild kinetic tremor and urinary symptoms persisted. He completed a 2-month rehabilitation program and was subsequently discharged home.

A 26-year-old Saudi male presented with a 3-week history of progressive dysarthria and unsteady gait, followed by cognitive slowing and behavioral changes such as apathy and irritability. His speech deteriorated to near mutism, coinciding with reduced interest in daily activities and episodes of anger. He reported a long-standing history of consuming raw camel milk. There was no history of fever, headache, hearing or vision loss, sensory complaints, sphincter dysfunction, weight loss, or substance use.

On examination, he was alert and oriented but showed weak eye contact, impaired short-term recall, and difficulty with abstract reasoning. Language function (comprehension, naming, reading, writing) was preserved, but speech remained severely dysarthric.

Neurological findings included saccadic intrusions, VOR overshoot, decreased visual acuity, and mild parkinsonian features—namely bradykinesia and rigidity, more prominent on the right. He also exhibited ataxia, impaired proprioception, reduced vibration and pinprick sensation, and a broad-based, imbalanced gait with reduced arm swing. Motor strength was normal.

Laboratory investigations revealed normal hematologic and metabolic profiles. ESR was elevated (63 mm/h), and CRP was mildly raised (9.4 mg/L). Brucella serology (BRUCELLACAPT) was markedly elevated (>1:5120). Workup for Wilson’s disease, HIV, and urine toxicology were negative. CSF analysis revealed clear fluid with:

Brain MRI showed extensive bilateral T2/FLAIR hyperintensities involving the basal ganglia, thalami, mammillary bodies, hippocampi, hypothalamus, optic radiations, substantia nigra, and periaqueductal gray matter, with mild restricted diffusion on DWI (Figure 2).

The patient was started on an anti-Brucella regimen; however, the specific antibiotic combination, dosage, and duration were not fully documented in the medical record. On outpatient follow-up, he showed partial clinical improvement (Figure 3).

A total of five published cases of neurobrucellosis presenting with parkinsonian features have been identified in the literature. These cases are summarized in Table 1. They represent a wide demographic range, with patients aged between 23 and 78 years and include both male and female individuals, indicating no clear demographic predilection. Notably, cases were included only if the clinical description specifically mentioned tremor, bradykinesia, rigidity, or other parkinsonism-related signs, in keeping with the neurological syndrome of interest.

All five cases exhibited parkinsonian motor symptoms, though the severity and combination of features varied. Tremor was a consistent finding, ranging from resting tremor to parkinsonian-like tremors that were static or stress-exacerbated. For example, Jin et al. described a patient with a parkinsonian-like tremor without other classical features of Parkinson’s disease (Jin et al., 2013), while Yasin et al. reported a more complete parkinsonian syndrome with tremor, rigidity, and bradykinesia (Yasin and Moghtader Mojdehi, 2014). Other cases, such as those reported by Shoaei et al. and Molins et al., also documented classic parkinsonian rigidity and slow gait (Shoaei et al., 2007; Molins et al., 1987).

In addition to parkinsonism, three patients presented with cognitive or psychiatric manifestations, such as hallucinations, behavioral changes, or frontal lobe dysfunction. The 2008 Iranian case described by Shoaei et al. involved a 26-year-old male with psychosis and parkinsonian symptoms (Ghaffarinejad et al., 2008). Focal neurological deficits, including hemiparesis, were noted in two patients (Shoaei et al., 2007; Yasin and Moghtader Mojdehi, 2014), and seizures were reported in one case (Jin et al., 2013).

All cases underwent confirmatory diagnostic workup. Serologic testing for Brucella (e.g., Rose Bengal, Wright, and 2-ME tests) was positive in all five cases. CSF analysis revealed lymphocytic pleocytosis and elevated protein in most cases. Although CSF culture results were often negative, these were complemented by positive serology or other microbiological evidence.

MRI findings included white matter hyperintensities, basal ganglia T2 changes, and meningeal enhancement in some patients (Shoaei et al., 2007; Yasin and Moghtader Mojdehi, 2014; Ghaffarinejad et al., 2008). EEG, when performed, showed nonspecific slowing (Jin et al., 2013; Ghaffarinejad et al., 2008). These variable findings illustrate the need for high clinical suspicion and a comprehensive diagnostic approach, especially in endemic regions.

All patients received multidrug antibiotic regimens, typically including doxycycline, rifampin, ceftriaxone, or trimethoprim-sulfamethoxazole. Treatment durations were prolonged, reflecting the intracellular persistence of Brucella spp. Corticosteroids were added in selected cases to control inflammatory complications.

Clinical outcomes were generally favorable with appropriate therapy. Most patients showed resolution or significant improvement of parkinsonian symptoms. However, residual deficits such as hearing loss or behavioral changes persisted in some cases (Shoaei et al., 2007). These findings reinforce the importance of early recognition and sustained treatment (Shoaei et al., 2007; Ghaffarinejad et al., 2008).